Medical diagnostics company Guardant Health has sued rival Natera in California federal court for allegedly stealing trade ...

The lawsuit claims Natera aggressively recruited bioinformatics scientists from Guardant to “jumpstart its lagging position ...

As of December 2024, Guardant held $840 million of cash and marketable securities. However, it burned through approximately $390 million in 2022, $345 million in 2023, and $275 million in 2024.

This report describes and explains the liquid biopsy for cancer diagnostics market and covers 2019-2024, termed the historic ...

Craig-Hallum analyst William Bonello maintained a Buy rating on Navitas Semiconductor (NVTS – Research Report) today. The company’s shares ...

The recent wildfires in Los Angeles are just the latest in a series of natural disasters that have disrupted cancer care.

Natera Inc. poached Guardant Health Inc. employees to steal trade secrets and jumpstart its “lagging position” in the early cancer test industry, according to a federal lawsuit. Former Guardant ...

Guardant Health stock hit a 13-month high Tuesday after Medicare officials agreed to pay for the company's colon cancer blood test. AUSTIN, Texas, January 17, 2025--Natera, Inc. (NASDAQ: NTRA), a ...

Delaware federal judge reverses jury verdict in CareDx’s favour | Natera’s patents covering organ transplant testing ...

Scotiabank raised the firm’s price target on Guardant Health (GH) to $52 from $47 and keeps an Outperform rating on the shares. Guardant Health ...